In the rapidly evolving field of inflammasome therapeutics, the need for innovative approaches to overcome the preclinical and clinical hurdles is more critical than ever.
Discover & Develop Selective, Clinically Validated & Novel Covalent Therapeutics to Expand the Targetable Proteome & Non-Cystine Amino Acid Space in Oncology, Immunology & B
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
